Rexahn Pharmaceuticals) announced Monday that it has been granted a European patent for its anti-cancer compounds.
The patent covers several new compounds, the process for their preparation, their pharmaceutical composition and a method for producing an anti-spreading effect in cancer cells.
The European patent will also cover Rexahn's pre-clinical compound RX-5902, for which human trials are expected to start this year.
"The issuance of this patent will enhance the commercial potential of RX-5902 in Europe- one of the largest markets of cancer therapeutics in the world, and further strengthens our overall global intellectual property position in oncology," said president Rick Soni.
RX-5902 is an oral agent that shows potent anti-tumor properties in several tumors, including melanoma.
Rexahn develops therapies for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. The company currently has three drug candidates in phase II clinical trials, Archexin, Serdaxin, and Zoraxel.
No comments:
Post a Comment